49 research outputs found
Nanoparticle-Assisted Water-Flooding in Berea Sandstones
The use of nanoparticles to improve reservoir characterization or to enhance oil recovery (EOR) has recently received intensive interest; however, there are still many unresolved questions. This work reports a systematic study of the effect of rutile TiO2 nanoparticle-assisted brine flooding. Rutile ellipsoid TiO2 nanoparticles were synthesized and stabilized by trisodium citrate dihydrate for brine flooding of water-wet Berea sandstone cores. Careful characterization of the rock samples and nanomaterials before and after the flooding was conducted, and the relative contributions to the modified flooding results from the stabilizer and the nanoparticles of different concentrations were examined. The oil recovery performance was evaluated both at the breakthrough (BT) point and at the end of flooding (âŒ3.2 pore volumes). Nanoparticle migration behavior was also investigated in order to understand the potential mechanisms for oil recovery. The results showed that both nanoparticle transport rate and EOR effect were strongly dependent on the particle concentration. The oil recovery efficiency at the BT point was found to increase at low nanoparticle concentrations but decrease at higher values. A maximum 33% increase of the recovery factor was observed at the BT point for a TiO2 concentration of 20 ppm, but higher nanoparticle concentrations usually had higher ultimate recovery factors. The presence of an oil phase was found to accelerate the particle migration though the core. The discussion of various mechanisms suggested that the improvement in the mobility ratio, possible wettability change, and log-jamming effect were responsible for the observed phenomena
Can sulphur improve the nutrient uptake, partitioning, and seed yield of sesame?
Sulphur (S) is considered to improve the nutrient uptake of plants due to its synergistic relationship with other nutrients. This could ultimately enhance the seed yield of oilseed crops. However, there is limited quantitative information on nutrient uptake, distribution, and its associated impacts on seed yield of sesame under the S application. Thus, a two-year field study (2018 and 2019) was conducted to assess the impacts of different S treatments (S-0 = Control, S-20 = 20, S-40 = 40, and S-60 = 60 kg ha(-1)) on total dry matter production, nitrogen, phosphorus, potassium, S uptake and distribution at the mid-bloom stage and physiological maturity. Furthermore, treatment impacts were studied on the number of capsules per plant, number of seeds per capsule, thousand seed weight, and seed yield at physiological maturity in sesame. Compared to S-0, over the years, treatment S-40 significantly increased the total uptake of nitrogen, phosphorus, potassium, and S (by 13, 22, 11% and 16%, respectively) at physiological maturity, while their distribution by 13, 36, 14, and 24% (in leaves), 12, 15, 11, and 15% (in stems), 15, 42, 18, and 10% (in capsules), and 14, 22, 9, and 15% (in seeds), respectively. Enhanced nutrient uptake and distribution in treatment S-40 improved the total biomass accumulation (by 28%) and distribution in leaves (by 34%), stems (by 27%), capsules (by 26%), and seeds (by 28%), at physiological maturity, as compared to S-0. Treatment S-40 increased the number of capsules per plant (by 13%), number of seeds per capsule (by 11%), and thousand seed weight (by 6%), compared to S-0. Furthermore, over the years, relative to control, sesame under S-40 had a higher seed yield by 28% and enhanced the net economic returns by 44%. Thus, our results suggest that optimum S level at the time of sowing improves the nutrient uptake and distribution during the plant lifecycle, which ultimately enhances total dry matter accumulation, seed yield, and net productivity of sesame
Relationship between Ketones, Ghrelin, and, Appetite on Isocaloric Diets with Varying Carbohydrate Quality and Amount: Results from a Randomized Controlled Trial in People with Obesity (CARBFUNC)
Background - Low-carbohydrate high-fat (LCHF) diets may suppress the increase in appetite otherwise seen after diet-induced fat loss. However, studies of diets without severe energy restriction are lacking, and the effects of carbohydrate quality relative to quantity have not been directly compared.
Objectives - To evaluated short- (3 mo) and long-term (12 mo) changes in fasting plasma concentrations of total ghrelin, ÎČ-hydroxybutyrate (ÎČHB), and subjective feelings of appetite on 3 isocaloric eating patterns within a moderate caloric range (2000â2500 kcal/d) and with varying carbohydrate quality or quantity.
Methods - We performed a randomized controlled trial of 193 adults with obesity, comparing eating patterns based on âacellularâ carbohydrate sources (e.g., flour-based whole-grain products; comparator arm), âcellularâ carbohydrate sources (minimally processed foods with intact cellular structures), or LCHF principles. Outcomes were compared by an intention-to-treat analysis using constrained linear mixed modeling. This trial was registered at clinicaltrials.gov as NCT03401970.
Results - Of the 193 adults, 118 (61%) and 57 (30%) completed 3 and 12 mo of follow-up. Throughout the intervention, intakes of protein and energy were similar with all 3 eating patterns, with comparable reductions in body weight (5%â7%) and visceral fat volume (12%â17%) after 12 mo. After 3 mo, ghrelin increased significantly with the acellular (mean: 46 pg/mL; 95% CI: 11, 81) and cellular (mean: 54 pg/mL; 95% CI: 21, 88) diets but not with the LCHF diet (mean: 11 pg/mL; 95% CI: â16, 38). Although ÎČHB increased significantly more with the LCHF diet than with the acellular diet after 3 m (mean: 0.16 mmol/L; 95% CI: 0.09, 0.24), this did not correspond to a significant group difference in ghrelin (unless the 2 high-carbohydrate groups were combined [mean: â39.6 pg/mL; 95% CI: â76, â3.3]). No significant between-group differences were seen in feelings of hunger.
Conclusions - Modestly energy-restricted isocaloric diets differing in carbohydrate cellularity and amount showed no significant differences in fasting total ghrelin or subjective hunger feelings. An increase in ketones with the LCHF diet to 0.3â0.4 mmol/L was insufficient to substantially curb increases in fasting ghrelin during fat loss
A source of resistance against yellow mosaic disease in soybeans correlates with a novel mutation in a resistance gene
Yellow mosaic disease (YMD) is one of the major devastating constraints to soybean production in Pakistan. In the present study, we report the identification of resistant soybean germplasm and a novel mutation linked with disease susceptibility. Diverse soybean germplasm were screened to identify YMD-resistant lines under natural field conditions during 2016-2020. The severity of YMD was recorded based on symptoms and was grouped according to the disease rating scale, which ranges from 0 to 5, and named as highly resistant (HR), moderately resistant (MR), resistant (R), susceptible (S), moderately susceptible (MS), and highly susceptible (HS), respectively. A HR plant named âNBG-SG Soybeanâ was identified, which showed stable resistance for 5 years (2016-2020) at the experimental field of the National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan, a location that is a hot spot area for virus infection. HS soybean germplasm were also identified as NBG-47 (PI628963), NBG-117 (PI548655), SPS-C1 (PI553045), SPS-C9 (PI639187), and cv. NARC-2021. The YMD adversely affected the yield and a significant difference was found in the potential yield of NBG-SG-soybean (3.46 ± 0.13a t/ha) with HS soybean germplasm NARC-2021 (0.44 ± 0.01c t/ha) and NBG-117 (1.12 ± 0.01d t/ha), respectively. The YMD incidence was also measured each year (2016-2020) and data showed a significant difference in the percent disease incidence in the year 2016 and 2018 and a decrease after 2019 when resistant lines were planted. The resistance in NBG-SG soybean was further confirmed by testing for an already known mutation (SNP at 149th position) for YMD in the Glyma.18G025100 gene of soybean. The susceptible soybean germplasm in the field was found positive for the said mutation. Moreover, an ortholog of the CYR-1 viral resistance gene from black gram was identified in soybean as Glyma.13G194500, which has a novel deletion (28bp/90bp) in the 5`UTR of susceptible germplasm. The characterized soybean lines from this study will assist in starting soybean breeding programs for YMD resistance. This is the first study regarding screening and molecular analysis of soybean germplasm for YMD resistance
The development and validation of a scoring tool to predict the operative duration of elective laparoscopic cholecystectomy
Background: The ability to accurately predict operative duration has the potential to optimise theatre efficiency and utilisation, thus reducing costs and increasing staff and patient satisfaction. With laparoscopic cholecystectomy being one of the most commonly performed procedures worldwide, a tool to predict operative duration could be extremely beneficial to healthcare organisations.
Methods: Data collected from the CholeS study on patients undergoing cholecystectomy in UK and Irish hospitals between 04/2014 and 05/2014 were used to study operative duration. A multivariable binary logistic regression model was produced in order to identify significant independent predictors of long (>â90 min) operations. The resulting model was converted to a risk score, which was subsequently validated on second cohort of patients using ROC curves.
Results: After exclusions, data were available for 7227 patients in the derivation (CholeS) cohort. The median operative duration was 60 min (interquartile range 45â85), with 17.7% of operations lasting longer than 90 min. Ten factors were found to be significant independent predictors of operative durations >â90 min, including ASA, age, previous surgical admissions, BMI, gallbladder wall thickness and CBD diameter. A risk score was then produced from these factors, and applied to a cohort of 2405 patients from a tertiary centre for external validation. This returned an area under the ROC curve of 0.708 (SEâ=â0.013, pââ90 min increasing more than eightfold from 5.1 to 41.8% in the extremes of the score.
Conclusion: The scoring tool produced in this study was found to be significantly predictive of long operative durations on validation in an external cohort. As such, the tool may have the potential to enable organisations to better organise theatre lists and deliver greater efficiencies in care
Burden of disease scenarios for 204 countries and territories, 2022â2050: a forecasting analysis for the Global Burden of Disease Study 2021
Background: Future trends in disease burden and drivers of health are of great interest to policy makers and the public at large. This information can be used for policy and long-term health investment, planning, and prioritisation. We have expanded and improved upon previous forecasts produced as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and provide a reference forecast (the most likely future), and alternative scenarios assessing disease burden trajectories if selected sets of risk factors were eliminated from current levels by 2050. Methods: Using forecasts of major drivers of health such as the Socio-demographic Index (SDI; a composite measure of lag-distributed income per capita, mean years of education, and total fertility under 25 years of age) and the full set of risk factor exposures captured by GBD, we provide cause-specific forecasts of mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) by age and sex from 2022 to 2050 for 204 countries and territories, 21 GBD regions, seven super-regions, and the world. All analyses were done at the cause-specific level so that only risk factors deemed causal by the GBD comparative risk assessment influenced future trajectories of mortality for each disease. Cause-specific mortality was modelled using mixed-effects models with SDI and time as the main covariates, and the combined impact of causal risk factors as an offset in the model. At the all-cause mortality level, we captured unexplained variation by modelling residuals with an autoregressive integrated moving average model with drift attenuation. These all-cause forecasts constrained the cause-specific forecasts at successively deeper levels of the GBD cause hierarchy using cascading mortality models, thus ensuring a robust estimate of cause-specific mortality. For non-fatal measures (eg, low back pain), incidence and prevalence were forecasted from mixed-effects models with SDI as the main covariate, and YLDs were computed from the resulting prevalence forecasts and average disability weights from GBD. Alternative future scenarios were constructed by replacing appropriate reference trajectories for risk factors with hypothetical trajectories of gradual elimination of risk factor exposure from current levels to 2050. The scenarios were constructed from various sets of risk factors: environmental risks (Safer Environment scenario), risks associated with communicable, maternal, neonatal, and nutritional diseases (CMNNs; Improved Childhood Nutrition and Vaccination scenario), risks associated with major non-communicable diseases (NCDs; Improved Behavioural and Metabolic Risks scenario), and the combined effects of these three scenarios. Using the Shared Socioeconomic Pathways climate scenarios SSP2-4.5 as reference and SSP1-1.9 as an optimistic alternative in the Safer Environment scenario, we accounted for climate change impact on health by using the most recent Intergovernmental Panel on Climate Change temperature forecasts and published trajectories of ambient air pollution for the same two scenarios. Life expectancy and healthy life expectancy were computed using standard methods. The forecasting framework includes computing the age-sex-specific future population for each location and separately for each scenario. 95% uncertainty intervals (UIs) for each individual future estimate were derived from the 2·5th and 97·5th percentiles of distributions generated from propagating 500 draws through the multistage computational pipeline. Findings: In the reference scenario forecast, global and super-regional life expectancy increased from 2022 to 2050, but improvement was at a slower pace than in the three decades preceding the COVID-19 pandemic (beginning in 2020). Gains in future life expectancy were forecasted to be greatest in super-regions with comparatively low life expectancies (such as sub-Saharan Africa) compared with super-regions with higher life expectancies (such as the high-income super-region), leading to a trend towards convergence in life expectancy across locations between now and 2050. At the super-region level, forecasted healthy life expectancy patterns were similar to those of life expectancies. Forecasts for the reference scenario found that health will improve in the coming decades, with all-cause age-standardised DALY rates decreasing in every GBD super-region. The total DALY burden measured in counts, however, will increase in every super-region, largely a function of population ageing and growth. We also forecasted that both DALY counts and age-standardised DALY rates will continue to shift from CMNNs to NCDs, with the most pronounced shifts occurring in sub-Saharan Africa (60·1% [95% UI 56·8â63·1] of DALYs were from CMNNs in 2022 compared with 35·8% [31·0â45·0] in 2050) and south Asia (31·7% [29·2â34·1] to 15·5% [13·7â17·5]). This shift is reflected in the leading global causes of DALYs, with the top four causes in 2050 being ischaemic heart disease, stroke, diabetes, and chronic obstructive pulmonary disease, compared with 2022, with ischaemic heart disease, neonatal disorders, stroke, and lower respiratory infections at the top. The global proportion of DALYs due to YLDs likewise increased from 33·8% (27·4â40·3) to 41·1% (33·9â48·1) from 2022 to 2050, demonstrating an important shift in overall disease burden towards morbidity and away from premature death. The largest shift of this kind was forecasted for sub-Saharan Africa, from 20·1% (15·6â25·3) of DALYs due to YLDs in 2022 to 35·6% (26·5â43·0) in 2050. In the assessment of alternative future scenarios, the combined effects of the scenarios (Safer Environment, Improved Childhood Nutrition and Vaccination, and Improved Behavioural and Metabolic Risks scenarios) demonstrated an important decrease in the global burden of DALYs in 2050 of 15·4% (13·5â17·5) compared with the reference scenario, with decreases across super-regions ranging from 10·4% (9·7â11·3) in the high-income super-region to 23·9% (20·7â27·3) in north Africa and the Middle East. The Safer Environment scenario had its largest decrease in sub-Saharan Africa (5·2% [3·5â6·8]), the Improved Behavioural and Metabolic Risks scenario in north Africa and the Middle East (23·2% [20·2â26·5]), and the Improved Nutrition and Vaccination scenario in sub-Saharan Africa (2·0% [â0·6 to 3·6]). Interpretation: Globally, life expectancy and age-standardised disease burden were forecasted to improve between 2022 and 2050, with the majority of the burden continuing to shift from CMNNs to NCDs. That said, continued progress on reducing the CMNN disease burden will be dependent on maintaining investment in and policy emphasis on CMNN disease prevention and treatment. Mostly due to growth and ageing of populations, the number of deaths and DALYs due to all causes combined will generally increase. By constructing alternative future scenarios wherein certain risk exposures are eliminated by 2050, we have shown that opportunities exist to substantially improve health outcomes in the future through concerted efforts to prevent exposure to well established risk factors and to expand access to key health interventions
Impact of opioid-free analgesia on pain severity and patient satisfaction after discharge from surgery: multispecialty, prospective cohort study in 25 countries
Background: Balancing opioid stewardship and the need for adequate analgesia following discharge after surgery is challenging. This study aimed to compare the outcomes for patients discharged with opioid versus opioid-free analgesia after common surgical procedures.Methods: This international, multicentre, prospective cohort study collected data from patients undergoing common acute and elective general surgical, urological, gynaecological, and orthopaedic procedures. The primary outcomes were patient-reported time in severe pain measured on a numerical analogue scale from 0 to 100% and patient-reported satisfaction with pain relief during the first week following discharge. Data were collected by in-hospital chart review and patient telephone interview 1 week after discharge.Results: The study recruited 4273 patients from 144 centres in 25 countries; 1311 patients (30.7%) were prescribed opioid analgesia at discharge. Patients reported being in severe pain for 10 (i.q.r. 1-30)% of the first week after discharge and rated satisfaction with analgesia as 90 (i.q.r. 80-100) of 100. After adjustment for confounders, opioid analgesia on discharge was independently associated with increased pain severity (risk ratio 1.52, 95% c.i. 1.31 to 1.76; P < 0.001) and re-presentation to healthcare providers owing to side-effects of medication (OR 2.38, 95% c.i. 1.36 to 4.17; P = 0.004), but not with satisfaction with analgesia (beta coefficient 0.92, 95% c.i. -1.52 to 3.36; P = 0.468) compared with opioid-free analgesia. Although opioid prescribing varied greatly between high-income and low- and middle-income countries, patient-reported outcomes did not.Conclusion: Opioid analgesia prescription on surgical discharge is associated with a higher risk of re-presentation owing to side-effects of medication and increased patient-reported pain, but not with changes in patient-reported satisfaction. Opioid-free discharge analgesia should be adopted routinely
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial
Background
Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects.
Methods
FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 years or older, had a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked to treatment allocation. Functional status was assessed at 6 months and 12 months after randomisation. Patients were analysed according to their treatment allocation. This trial is registered with the ISRCTN registry, number ISRCTN83290762.
Findings
Between Sept 10, 2012, and March 31, 2017, 3127 patients were recruited. 1564 patients were allocated fluoxetine and 1563 allocated placebo. mRS data at 6 months were available for 1553 (99·3%) patients in each treatment group. The distribution across mRS categories at 6 months was similar in the fluoxetine and placebo groups (common odds ratio adjusted for minimisation variables 0·951 [95% CI 0·839â1·079]; p=0·439). Patients allocated fluoxetine were less likely than those allocated placebo to develop new depression by 6 months (210 [13·43%] patients vs 269 [17·21%]; difference 3·78% [95% CI 1·26â6·30]; p=0·0033), but they had more bone fractures (45 [2·88%] vs 23 [1·47%]; difference 1·41% [95% CI 0·38â2·43]; p=0·0070). There were no significant differences in any other event at 6 or 12 months.
Interpretation
Fluoxetine 20 mg given daily for 6 months after acute stroke does not seem to improve functional outcomes. Although the treatment reduced the occurrence of depression, it increased the frequency of bone fractures. These results do not support the routine use of fluoxetine either for the prevention of post-stroke depression or to promote recovery of function.
Funding
UK Stroke Association and NIHR Health Technology Assessment Programme
Recommended from our members
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990â2021: a systematic analysis for the Global Burden of Disease Study 2021
BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56â604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100â000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100â000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100â000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100â000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100â000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation
The role of dietary fibers in metabolic diseases
Abstract
Obesity and dyslipidemia are major risk factors for type 2 diabetes, cardiovascular diseases (CVD), cancer, and musculoskeletal disorders. In prevention, the major goal is to limit calorie consumption and to reduce LDL-C and triglyceride. Dietary fiber (DF) intake is inversely related to body weight gain, insulin resistance, dyslipidemia, and CVD. This thesis investigated the effects of the DFs polydextrose (PDX) and lignin-rich insoluble residue (INS) from brewerâs spent grain (BSG) on lipid metabolism and obesity in diet-induced obese mice.
In study 1, PDX was investigated on lipid metabolism in Western-diet-fed mice. We found that PDX reduced fasting plasma cholesterol and triglyceride, food intake, and increased bacteria such as Allobaculum, Bifidobacterium and Coriobacteriaceae in the gut. These changes in the gut microbiota with PDX were associated with downregulation of the genes Fiaf, Dgat1 and Cd36, and upregulation of Fxr in the intestine. We suggest that the hypolipidemic effect of PDX is exerted via diet-induced modification of gut microbiota and gene expression.
In study II, INS from BSG was studied for its degradation products in mice fed with a fiber-deficient diet. We found that INS was partially degraded by gut microbiota and contributed to the phenolic pool. The major metabolite in mouse urine was 4-methylcatechol, a degradation product of lignin.
In study III, the effects of INS from BSG were studied on lipid metabolism and obesity in high-fat diet-fed mice. INS showed hypocholesterolemic effects, reduced body weight and hepatic steatosis, and increased bacterial diversity, Clostridium leptum, and Bacteroides. INS increased bile acid excretion in the feces and upregulated the genes Srebp2, Hmgcr, Ldlr, Cyp7a1, Pparα, Fxr and Pxr in the liver. The present results suggest that INS from BSG induced beneficial systemic changes via bile acid and gut microbiota.
In study IV, PDX was investigated for food intake and appetite-related parameters in healthy and overweight females in an acute study. A midmorning preload of 12.5 g PDX reduced hunger by 31.4% during satiation period while there was no significant change in energy intake compared to placebo. In addition, PDX lowered plasma insulin significantly, by 15.7%, and increased GLP-1 by 39.9%. PDX may reduce appetite, but a larger trial would be needed.TiivistelmÀ
Liikalihavuus ja rasvatasapainon hĂ€iriöt ovat riskitekijöitĂ€ sydĂ€n- ja verisuonisairauksien, tyypin 2 diabeteksen, syövĂ€n sekĂ€ luuston ja lihaksiston sairauksien kehittymiseen. NĂ€iden sairauksien ehkĂ€isyssĂ€ pÀÀasiallisena tavoitteena on vĂ€hentÀÀ energiansaantia, LDL-kolesterolia ja triglyseridejĂ€. Ruoan ravintokuitujen saannin on osoitettu olevan yhteydessĂ€ painon ja plasman rasvatasojen laskuun sekĂ€ sydĂ€n- ja verisuonisairauksien vĂ€henemiseen. TĂ€ssĂ€ tutkimuksessa selvitettiin ravintokuitu polydekstroosin (PDX) ja viljanjyvien prosessoinnista ylijÀÀvĂ€n (BSG, brewerâs spent grain) ligniinipitoisen liukenemattoman sivutuotteen (INS) merkitystĂ€ rasva-aineenvaihduntaan ja aineenvaihduntasairauksiin liikalihavilla hiirillĂ€.
Tutkimuksessa I tarkasteltiin ravintokuitu PDX:n vaikutusta rasvojen aineenvaihduntaan lÀnsimaisella ruokavaliolla ruokituilla hiirillÀ. Tutkimus osoitti, ettÀ ruokavalioon lisÀtty PDX alensi plasman kolesteroli- ja triglyseriditasoja paastossa sekÀ hillitsi ravinnonottoa ja lisÀsi Allobaculum-, Bifidobacterium- ja Coriobacteriaceae-suolistobaktereja. NÀmÀ suolistomikrobiston muutokset ovat yhteydessÀ Fiaf, Dgat1 ja Cd36 -geenien ilmentymistasojen laskuun ja Fxr -geenin ilmentymistason nousuun PDX-lisÀruokittujen hiirien suolistossa. PDX:n hypolipideeminen vaikutus nÀyttÀisi vÀlittyvÀn ruokavaliosta johtuvan suoliston geenien ilmentymisen ja suolistomikrobiston muuttumisen kautta.
Tutkimuksessa II tarkasteltiin runsaasti ligniiniÀ sisÀltÀvÀn INS:n hajoamistuotteiden vaikutusta aineenvaihduntaan hiirillÀ, joiden ruokavaliossa on vÀhemmÀn kuitua. Tutkimuksessa havaittiin, ettÀ suolistomikrobit hajottivat ravintokuitu INS:n osittain fenoliyhdisteiksi verenkiertoon. INS lisÀsi virtsassa 4-metyylikatekolin mÀÀrÀÀ, joka on ligniinin hajoamistuote.
Tutkimuksessa III tarkasteltiin INS-lisÀyksen vaikutusta rasva-aineenvaihduntaan ja liikalihavuuteen korkearasvapitoisella ruokavaliolla ruokituilla hiirillÀ. Tulokset osoittivat, ettÀ INS-lisÀys ruokavalioon alensi kolesterolia ja elÀimen painoa sekÀ vÀhensi maksan rasvoittumista ja lisÀsi vallitsevien bakteerien monimuotoisuutta, Clostridium leptum- ja Bacteroides -bakteereja. INS lisÀsi sappihappojen erittymistÀ ulosteeseen ja Srebp2, Hmgcr, Ldlr, Cyp7a1, Pparα, Fxr ja Pxr -geenien ilmentymistÀ maksassa. Tuloksemme osoittivat, ettÀ BSG-ylijÀÀmÀtuotteesta saatu ligniinipitoinen INS sai aikaan hyödyllisiÀ systeemisiÀ vaikutuksia suoliston mikrobiston ja sappihappojen muutosten kautta.
Tutkimuksessa IV tarkasteltiin PDX:n vaikutusta ravinnonottoon ja ruokahaluun vaikuttaviin muuttujiin normaalipainoisilla ja liikalihavilla naisilla akuutissa tutkimuksessa. Tulosten mukaan ravintokuitu PDX:n nauttiminen aamiaisella vÀhensi nÀlÀntunnetta (31,4 %) seuraavalla aterioinnilla, kun taas plasebolla ei ollut vaikutusta. LisÀksi PDX alensi merkitsevÀsti insuliinitasoa (15,7 %) ja nosti GLP-1-tasoa (39,9 %). PDX vaikuttaisi vÀhentÀvÀn ruokahalua, mutta lisÀtutkimuksia tarvitaan